Search clinical trials for: PEG IFN alfa-2a

Total 1116 results

Beijing Ditan Hospital

Unknown

The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
Beijing Ditan Hospital

Unknown

The Changes of Treg Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
Beijing Ditan Hospital

Unknown

The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
Yao Xie

Unknown

The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy

Chronic Hepatitis B Infection

China
Beijing Ditan Hospital

Unknown

The Changes of Cytokines During Antiviral Therapy

Chronic Hepatitis B Infection

China
Gilead Sciences

Completed

Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)

Chronic Hepatitis Delta

France, Moldova, Republic of, Romania, Russian Federation
Beijing Ditan Hospital

Unknown

Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues

Chronic Hepatitis B

China
Hoffmann-La Roche

Completed

A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous Administration

Healthy Volunteers

New Zealand, Taiwan, Australia, Hong Kong, Singapore
Beijing 302 Hospital

Unknown

Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B

Chronic Hepatitis B

China
Hoffmann-La Roche

Completed

A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue

Hepatitis B, Chronic

Thailand, China, Italy, United Kingdom, Korea, Republic of, Taiwan, Austria, Bulgaria, Germany, New Zealand, France, Poland, Portugal, Romania, Greece
Hoffmann-La Roche

Completed

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Hepatitis C, Chronic

Belgium, United States, Germany, Canada, Austria, Switzerland, Puerto Rico, Australia, Brazil, Mexico
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

Chronic Hepatitis C (CHC)

Japan
Hepatera Ltd.

Completed

Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection

Chronic Hepatitis D Infection
Tibotec BVBA

Completed

An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

Chronic Hepatitis C

France, Spain, Belgium, Germany, Austria, Netherlands
Hoffmann-La Roche

Completed

An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Belgium, France, Germany, Sweden, Switzerland, Turkey, Greece, Ireland, Taiwan, Estonia, Hungary, Italy, Romania, United Kingdom, Serbia, Morocco, Portugal, Saudi Arabia, Egypt, Pakistan, Lebanon, Macedonia, The Former Yugoslav Republic... and more
M.D. Anderson Cancer Center

Terminated

Pegasys in Patients With Chronic Myeloid Leukemia (CML)

Leukemia

United States
Merck Sharp & Dohme LLC
Novartis Pharmaceuticals

Completed

Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

Chronic Hepatitis C

United States
HepNet Study House, German Liverfoundation
Gilead Sciences; Hannover Medical School; Hoffmann-La Roche

Completed

HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis (HIDIT-II)

Hepatitis D

Germany, Greece, Romania
Merck Sharp & Dohme LLC

Completed

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)

Chronic Hepatitis C Infection
Merck Sharp & Dohme LLC

Completed

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

Hepatitis C, Chronic
Hoffmann-La Roche

Completed

A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)

Hepatitis D, Chronic

Romania
Pusan National University Hospital

Unknown

HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance

Chronic Hepatitis B

Korea, Republic of
Gilead Sciences

Completed

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Hong Kong, Spain, Taiwan, United States, Poland, France, Netherlands, Singapore, Australia, Canada, Italy, United Kingdom, Germany, Portugal, Romania, Greece, Turkey, India
National Taiwan University Hospital
National Science Council, Taiwan; Department of Health, Executive Yuan, R.O...

Terminated

Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load

Hepatitis C

Taiwan
Hoffmann-La Roche

Completed

A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection

Hepatitis C, Chronic

Australia, Canada, Mexico, New Zealand, Thailand, Argentina
Tibotec BVBA
Tibotec Pharmaceutical Limited

Completed

A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment

Hepatitis C, Chronic

United States, Australia, France, United Kingdom, Germany, Spain, Belgium, Israel, Canada, Brazil, Austria, Poland, Netherlands, Sweden, Switzerland, Puerto Rico
M.D. Anderson Cancer Center

Completed

Pegasys® in Patients With Myeloproliferative Diseases

Myeloproliferative Disorders

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas

Brain and Central Nervous System Tumors

United States
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

Hepatitis C, Chronic

United States, Puerto Rico
Baptist Health South Florida
Regeneron Pharmaceuticals

Withdrawn

Cemiplimab/Peg-Interferon-α in Advanced CSCC

Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Advanced Squamous Cell Carcinoma

United States
Hoffmann-La Roche

Completed

A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Hepatitis B, Chronic

Italy
Tibotec BVBA

Completed

A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection

Hepatitis C, Chronic

France, United Kingdom, Sweden
Beijing Kawin Technology Share-Holding Co., Ltd.

Completed

Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C

Chronic Hepatitis c

China
Vir Biotechnology, Inc.
Alnylam Pharmaceuticals

Active, not recruiting

Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

Australia, Hong Kong, Korea, Republic of, Malaysia, New Zealand, Thailand
Hoffmann-La Roche

Completed

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Hepatitis C, Chronic

Spain, United States, Germany, Canada, Austria, France
IRCCS San Raffaele
Hoffmann-La Roche; Abbott

Unknown

Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy

HIV Infections | Hepatitis C

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

Breast Cancer | Metastatic Cancer

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Hepatitis C

United States, Canada, Netherlands, Puerto Rico, Germany
Vertex Pharmaceuticals Incorporated

Terminated

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C

United States
Hoffmann-La Roche

Completed

Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus

Hepatitis C, Chronic

Brazil
Beijing Kawin Technology Share-Holding Co., Ltd.

Completed

A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C

Chronic Hepatitis C

China
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)

Hepatitis C

Taiwan
Vertex Pharmaceuticals Incorporated

Terminated

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype (CONCISE)

Hepatitis C, Chronic

United States, Austria, Canada, Germany, Israel, Poland
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Hepatitis C

Australia, Canada, France, Italy, Poland, United Kingdom, Germany, United States, Spain, Israel, Argentina, Puerto Rico, Austria
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

Chronic Hepatitis C

United States, Puerto Rico
Louis Stokes VA Medical Center

Completed

Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

Hepatitis C, Chronic | Cirrhosis

United States
Tibotec Pharmaceuticals, Ireland

Completed

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment (ASPIRE)

Hepatitis C

United States, Australia, France, United Kingdom, Belgium, Germany, Israel, Portugal, Canada, New Zealand, Russian Federation, Austria, Poland, Norway
Hoffmann-La Roche

Completed

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

Hepatitis C, Chronic

United States
Azienda Ospedaliera V. Cervello

Unknown

Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies (IFNRIBAHE)

Hemoglobinopathies

Italy
National Taiwan University Hospital
National Science Council, Taiwan; Department of Health, Executive Yuan, R.O...

Completed

Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR

Chronic Hepatitis C

Taiwan

3

Subscribe